Signed in as:
filler@godaddy.com
Current Projects
Australian Ustekinumab Real-world Observational Research (AURORA)
Lead Investigators: Dr Yoon-Kyo An, A/Prof Graham Radford-Smith, A/Prof Jakob Begun
Prospective Randomised Controlled Trial of Adult Patients with Perianal Fistulising Crohn’s Disease and Optimised Therapeutic Infliximab Levels (PROACTIVE).
Lead Investigators: A/Prof Susan Connor, A/Prof John Nik Ding
Study of TOfacitinib for the treatment of chronic PouchITis (STOPit)
Lead Investigators:
Clinical outcomes and prognostic factors of Acute Severe Ulcerative Colitis in Asia-Pacific
Lead Investigator: Dr Yoon-Kyo An
Developing Australian and New Zealand Inflammatory Bowel Disease clinical quality indicators
Lead Investigator: A/Prof Peter De Cruz
Management of moderate POstoperative recurrence in Crohn’s disease: a randoMizEd contROLled trial of therapeutic escalation.
The POMEROL trial.
Lead Investigator: A/Prof Peter De Cruz
Virtual Biologics Clinics as a platform to achieve values-based healthcare in IBD
Lead Investigator: A/Prof Peter De Cruz
Biologic Options for Optimal Second-line Treatment for fistulising Crohn's Disease
Lead Investigator: A/Prof John Ding / Dr Imogen Hartley
Publications
- Lim E, Thai M, An YK, Hendy P, Alchlaihawi M, Leong R, . . .Begun J. High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease. GastroHep. 2024 Jun, 3686618, https://doi.org/10.1155/2024/3686618
- Mortlock S, Lord A, Montgomery G, Zakrzewski M, Simms LA, Krishnaprasad K. . . Radford-Smith GL. An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis, JCC. 2023. 17(2), 277–288. https://doi.org/10.1093/ecco-jcc/jjac121
- De Gregorio M, Lee T, Krishnaprasad K, Amos G, An Y-K, Bastian-Jordan M, . . . Ding NS. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiological Outcomes in Crohn’s Perianal Fistulas. Clin Gastroenterol Hepatol. 2022 Jun, 20(6), 1306
- Krishnaprasad K, Walsh A, Begun J, Bell S, Carter D, Grafton R, . . . Connor S. Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for Inflammatory Bowel Disease. Scand J Gastroenterol. 2020 Nov 8; 1-8.
- Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, . . . De Cruz P. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020 Nov;52(10):1551-1562.
- Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, . . . De Cruz P. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol. 2020 Aug 14;26(30):4428-4441.
- Wu Y, Ghaly S, Kerr S, Jackson B, Hanigan K, Martins D, . . . Bampton PA. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients. Dig Dis Sci. 2019 Sep 6.
- Romagnoni A, Jégou S, Van Steen K, Wainrib G, Hugot J-P. Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Sci Rep. 2019 Jul 17;9(1):10351.
- Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, . . . Kelsen J. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflamm Bowel Dis.2019 May 29.
- Momozawa Y, Dmitrieva J, Théâtre E, Deffontaine V, Rahmouni S, Charloteaux B, . . . Gori A-S. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun. 2018 Jun 21;9(1):2427.
- Roberts RL, Wallace MC, Seinen ML, Van Bodegraven AA, Krishnaprasad K, Jones GT, . . . Prosser R. Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 May 16.
- Chen G-B, Lee SH, Montgomery GW, Wray NR, Visscher PM, Gearry RB, . . . Mahy G. Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. BMC Med Genet. 2017 Aug 29;18(1):94.
- Huang H, Fang M, Jostins L, Mirkov MU, Boucher G, Anderson CA, . . . Crins F. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017 Jun 28.
- Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, . . . Kelsen J. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jul;23(7):1240-1246.
- Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2017 Mar 7. pii: S1542-3565(17)30258-6.
- Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, . . . Krishnaprasad K. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. (First published: 19 December 2016)
- Ghaly S, Murray K, Baird A, Martin K, Prosser R, Mill J, Simms LA, Hart PH, Radford-Smith G, Bampton PA, Lawrance IC. High Vitamin D-Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease. Inflamm Bowel Dis. 2016 Oct;22(10):2456-64.
- Li D, Achkar J-P, Haritunians T, Jacobs JP, Hui KY, D'Amato M, . . . Niess J-H. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology. 2016 Oct;151(4):724-32.
- Bodea CA, Neale BM, Ripke S, Barclay M, Peyrin-Biroulet L, Chamaillard M, . . . D’Incà R. A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. Am J Hum Genet. 2016 May 5;98(5):857-68.
- Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, . . . Rosella O. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016 Jul;151(1):110-9.
- Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, . . . Chaudhary R. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Feb;10(2):149-58.
- Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, . . . Brand S. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 Jan 9;387(10014):156-67.
- Liu JZ, Van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, . . . Shah T. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 Sep;47(9):979-86.
- Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, . . . Hauser SL. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet.2015 Feb;47(2):172-9.
- Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, . . . Andrews JM. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014 Sep 14.
- Roberts RL, Wallace MC, Seinen ML, Krishnaprasad K, Chew A, Lawrance I, . . . Simms L. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol. 2014 Jun;109(6):925-7.
- Chen G-B, Lee SH, Brion M-JA, Montgomery GW, Wray NR, Radford-Smith GL, . . . International IBDGC. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum Mol Genet. 2014 Sep 1;23(17):4710-20.
- Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, . . . Törkvist L. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 2013;9(9):e1003723.
- Lawrance IC, Murray K, Batman B, Gearry RB, Grafton R, Krishnaprasad K, . . . Cooke SE. Crohn’s disease and smoking: is it ever too late to quit? J Crohns Colitis. 2013 Dec 15;7(12):e665-71.
- Doecke JD, Simms LA, Zhao ZZ, Huang N, Hanigan K, Krishnaprasad K, . . . Bampton P. Genetic Susceptibility in IBD: Overlap between Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2013 Feb;19(2):240-5.
- Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, . . . Anderson CA. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24.
- Krishnaprasad K, Andrews JM, Lawrance IC, Florin T, Gearry RB, Leong RWL, . . . Leach P. Inter-observer agreement for Crohn’s disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study. J Crohns Colitis. 2012 Apr;6(3):287-93.
- Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, . . . Burtt N. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011 Oct 9;43(11):1066-73.
- Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, . . . Latiano A. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011 Mar;43(3):246-52.
- Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, . . . Daly MJ. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011 Jan 13;7(1):e1001273.
- Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, . . . Roberts R. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010 Dec;42(12):1118-25.
- Lawrance IC, Radford‐Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, . . . Florin THJ. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010 Nov;25(11):1732-8.
